
Creatine for Women Over 40: Trials vs. the Marketing
Last updated October 12, 2026
Creatine for women 40+ reviewed against PubMed: muscle and bone trial data, brain-fog limits, kidney myths, dosing, and why lifting matters.
Longevity
Editorial guides on omega-3, inflammation, and other longevity topics in our current library. We add new guides as evidence and reader demand justify them.
What belongs here: omega-3 and inflammation-marker framing, plus other longevity products in the current library, with clear ceilings on what the evidence supports.
What does not: biohacker protocols, unregulated peptide shopping lists, or “anti-aging stack” rankings sold as clinical programs.
Evidence tools
Trial presets, label checks, dose floors, and physician-reviewed interaction pairs. Browser-only, nothing stored.

Last updated October 12, 2026
Creatine for women 40+ reviewed against PubMed: muscle and bone trial data, brain-fog limits, kidney myths, dosing, and why lifting matters.

Last updated October 16, 2026
Mitopure muscle trials, metabotype zero, pomegranate PK, sleep hype, and how urolithin A compares with NMN once you drop the longevity marketing script.

Last updated September 19, 2026
EPA and DHA lower inflammatory markers at the right dose, if the oil is still fresh. Ratios, triglyceride form, TOTOX limits, and the label traps to skip.